Pancreatic Cancer Research

ResearcherNational Cancer Centre JapanActive in the last 2 years

Mitsuhito Sasaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3754-9027; OpenAlex author ID A5001276027, A5027837608. Sources: OpenAlex.

Their work

Papers
19 (first author 5, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2019: 3 papers · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: 5 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 19

  1. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: results from an open-label, phase II study. Last author DOI 10.1016/j.esmogo.2026.100365↗
  2. Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer. Co-author DOI 10.1093/jjco/hyag044↗
  3. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. Co-author DOI 10.1016/j.ejca.2025.115424↗
  4. Covered self-expandable metallic stent placement for tumor bleeding from duodenal invasion in patients with unresectable pancreatic cancer. Co-author DOI 10.1002/deo2.361↗
  5. Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites. Co-author DOI 10.1016/j.pan.2024.03.015↗
  6. Fibroblast inhibition by tocilizumab enabled gemcitabine/nab-paclitaxel rechallenge for pancreatic cancer. Co-author DOI 10.1111/cas.15929↗
  7. Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study. First author DOI 10.1186/s13014-023-02367-5↗
  8. Correction: Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study. First author DOI 10.1186/s13014-023-02377-3↗
  9. Clinical course of anorexia-cachexia according to type of first-line chemotherapy for advanced pancreatic cancer Co-author DOI 10.21203/rs.3.rs-3048794/v1↗
  10. FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia - Nationwide Study Analysis. First author DOI 10.21873/anticanres.16601↗
  11. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-es… Co-author DOI 10.1016/j.ejca.2022.06.010↗
  12. A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s10147-021-02001-y↗
  13. Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. First author DOI 10.3390/diagnostics11071195↗
  14. The "histological replacement growth pattern" represents aggressive invasive behavior in liver metastasis from pancreatic cancer. Co-author DOI 10.1002/cam4.2954↗
  15. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort… Co-author DOI 10.1007/s00280-020-04110-3↗
  16. A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001484↗
  17. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. Co-author DOI 10.1007/s10637-018-0634-5↗
  18. Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study. Co-author DOI 10.2169/internalmedicine.2539-18↗
  19. New Era of Endoscopic Ultrasound-Guided Tissue Acquisition: Next-Generation Sequencing by Endoscopic Ultrasound-Guided Sampling for Pancreatic Cancer. First author DOI 10.3390/jcm8081173↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masafumi Ikeda · 17 shared papers, 2019–2026 · strength 2.46
  2. Hiroshi Imaoka · 15 shared papers, 2019–2026 · strength 2.27
  3. Shuichi Mitsunaga · 15 shared papers, 2019–2026 · strength 2.21
  4. Tomoyuki Satake · 6 shared papers, 2023–2026 · strength 1.18
  5. Taro Shibuki · 6 shared papers, 2021–2026 · strength 1.14
  6. Tomonao Taira · 5 shared papers, 2023–2026 · strength 1.00
  7. Kanae Inoue · 5 shared papers, 2023–2026 · strength 1.00
  8. Masato Ozaka · 5 shared papers, 2020–2026 · strength 0.78
  9. Chigusa Morizane · 5 shared papers, 2019–2026 · strength 0.63
  10. Takuji Okusaka · 5 shared papers, 2019–2023 · strength 0.58
  11. Naohiro Okano · 3 shared papers, 2022–2025 · strength 0.47
  12. Kazuo Watanabe · 3 shared papers, 2020–2023 · strength 0.43
  13. Yoshito Komatsu · 2 shared papers, 2025–2026 · strength 0.42
  14. Hiroaki Nagano · 2 shared papers, 2025–2026 · strength 0.42
  15. Akihiro Ohba · 3 shared papers, 2021–2023 · strength 0.42
  16. Makoto Ueno · 3 shared papers, 2020–2025 · strength 0.39
  17. Nobumasa Mizuno · 2 shared papers, 2023–2026 · strength 0.38
  18. Satoshi Kobayashi · 3 shared papers, 2020–2023 · strength 0.34
  19. Toru Otsuru · 2 shared papers, 2020–2026 · strength 0.33
  20. Junji Furuse · 2 shared papers, 2022–2025 · strength 0.32
  21. Masataka Amisaki · 1 shared paper, 2026 · strength 0.28
  22. Atsushi Ochiai · 2 shared papers, 2020–2023 · strength 0.25
  23. M Ueno · 1 shared paper, 2026 · strength 0.23
  24. Kenji Ikezawa · 1 shared paper, 2026 · strength 0.23
  25. Takeshi Terashima · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.